U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Amiodarone hydrochloride (marketed as Cordarone and Pacerone) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Amiodarone hydrochloride (marketed as Cordarone and Pacerone) Information

Amiodarone is a cardiac drug that is indicated for the management of life-threatening recurrent ventricular fibrillation (VF) or hemodynamically-unstable ventricular tachycardia (VT) refractory to other antiarrhythmic agents, or in patients intolerant of other agents used for these conditions.

Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.

Related Information

Labeling and Regulatory History from Drugs@FDA

Back to Top